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Abstract 
 
Colorectal cancer (CRC) is thought to be initiated by mutation of Adenomatous Polyposis 
Coli (APC), a tumour suppressor gene mutant in more than 80% of all human CRC cases. Loss of 
heterozygosity of the APC gene results in non-functioning alleles. This renders an APC protein 
incapable of maintaining proper Wnt signaling - critical in intestinal stem cell (ISC) homeostasis 
- preventing ISC differentiation and promoting a stem cell-like proliferative state. This increased 
Wnt activity raises Wnt target genes, including AXIN2, MYC, and the stem cell marker (LGR5) 
gene in tumours comparatively to adjacent tissue. Clock genes activate the transcription of their 
own repressors in a transcriptional/translational feedback loop (TTFL), in which CLOCK/BMAL1 
drive the expression of CRY and PER whose products in turn suppress CLOCK/BMAL1. A second 
TTFL regulates BMAL1.  The clock and its target genes confer rhythmic functions to many cellular 
processes including intestinal proliferation. I hypothesized that tumours will have disrupted 
circadian clock gene expression. To test this, APCmin/+ animal tumours and tissue were sampled 
over 24 hours using RT-qPCR. This revealed that circadian genes were less expressed in tumours, 
and that Wnt, cell cycle progression, and stem cell marker genes were more greatly expressed 
in tumours compared to adjacent tissue. Also, I hypothesized that tumorigenesis would increase 
under clock disruption. To test this, APCmin/+ were crossed with BMAL1 mice to create an APCmin  
; BMAL1-/- mice. These mice have a 2-fold increase in tumour counts while average size of 
tumours is smaller, implying disrupted clock fuels an increased induction of tumours.  Together, 
these data suggest that tumours suppress circadian clock function, and that completely 
disrupted circadian clock function increases tumorigenesis.   
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Chapter 1: Introduction 
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1.1 Cancer 
 
Half of all Canadians will develop cancer in their lifetime and of these disease victims, 25% 
will die from the disease. [1]  Cancer is defined as a process in which normal cells change 
progressively to transform into a neoplastic state. These cells acquire successive traits and 
capabilities enabling them to change into a collective of tumorigenic tissue of different and 
distinct cell types that interact and progress into invasive malignant cells . [2]  There are eight 
distinguishing traits in all cancers which contribute to tumour growth and metastatic 
transformation. These core traits invariably include sustained proliferative signaling, evasion of 
growth suppressors, resistance of cell death, causing replicative immortality, induction of 
angiogenesis, activation of invasion and metastasis, reprogramming of energy metabolism, and 
finally, evasion of the immune destruction. [2] Underlying these distinguishing traits is genomic 
instability which fuels the advancement of these traits and the development of disease.  
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1.2 Colorectal Cancer 
 
Colorectal cancer (CRC) is the 2nd most common cancer and accounts for 13% of all 
cancers in Canada [1]. Its incidence remains unchanged over the past 20 years with 1 in 14 men 
and 1 in 16 women likely to develop CRC in their lifetime. Approximately   5% of the incidence 
of CRC is due to an inherited germline mutation. [3] Studying inherited CRC has improved our 
understanding of factors and mechanisms at play in the sporadic development of disease. 
Tumorigenesis is a multistep process, and in CRC, tumours appear after an initial mutation in 
Adenomatous Polyposis Coli (APC) gene. Subsequently, other activation of oncogenes such as 
c-Myc followed by the inactivation of Tumour Suppressor Genes (TSGs), the latter having a 
greater impact on progression of disease. [4]  The inherited form of disease, familial 
adenomatous polyposis (FAP) is an autosomal dominant syndrome in which a germ-line 
mutated APC allele is inherited. [3] Nevertheless, more than 80% of all human CRC cases are 
initially caused by a somatic mutation of  APC, a mammalian tumour suppressor gene. Somatic 
APC gene mutations lead to a truncation in the APC protein and is believed to be an initiating 
step in formation of a dysplastic crypt for the development of an adenoma. Both germ-line and 
somatic mutations are within the same basic range of amino acid sequences on the protein for 
Axin or β-catenin binding. Mutations leading to a truncated APC protein occur most often 
before the Axin binding codons (the first serine alanine methionine proline (SAMP)) – at codon 
1580 – and at an initial 3 of a 20 amino acid coding repeat regions responsible in β-catenin 
binding. [5] 
However, adenoma to carcinoma transitions need multiple steps in genetic instability to 
occur as seen in Figure 1.1. In an incorporated Knudson “two-step” theory, biallelic APC gene loss 
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has an impact on growth of sporadic adenomas. A cell with loss of heterozygosity would then 
grow and proliferate into a small adenoma with some growth advantage. With increased 
proliferation, there is increased genetic instability and other subsequent independent mutations 
can occur, such as p53 or K-ras, driving increased progression in the transition from adenoma to 
carcinoma. [3] 
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                    Inactivation of APC  Mutation of K-Ras Subsequent mutations     
 
Figure 1.1 Model for Genetic progression in CRC .Inactivation of APC protein leads to a dysplastic crypt. 
Progression of adenoma can occur upon other mutations driving an adenomatous lesion phenotype. 
Chromosomal instability can then drive subsequent mutation in the adenoma to carcinoma transition. 
Adapted from [3] 
 
 
Figure 1.2 Schematic representation of the adenomatous polyposis coli (APC) protein and 
mutation histograms. (a) The 2,843 – amino acid APC protein and a representation of its interacting 
partners. In the amino-terminal central-third of APC, there are multiple independent 20-amino acid 
repeats that are β-catenin and many Axin protein binding sites. (b) Germ-line mutation frequencies and 
distribution in familial adenomatous polyposis patients in respect to APC-coding region. Nearly all 
mutations result in a truncation of protein. Codons 1061 and 1309 are “hot spot” mutations. (c) Somatic 
mutation frequencies and distribution in sporadic CRC. A mutation cluster region accumulate the most 
mutations. Codons 1309 and 1450 are “hot spot” mutations. Modified from [3]. 
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1.3 Wnt signaling and intestinal epithelium homeostasis 
 
APC protein is a key negative regulator in Wnt signaling: in the absence of Wnt ligand, APC 
protein forms a signaling destruction complex that targets cytosolic β-catenin for degradation. 
APC complexes with the protein Axin in order to promote a 2-step phosphorylation of β-catenin 
at several N-terminal residues– first by the enzyme casein kinase 1 and then by glycogen synthase 
kinase 3β (GSK3β). These phosphorylation steps target β-catenin for proteasomal degradation. 
Conversely, in the presence of a Wnt ligand, a transmembrane Frizzled protein and a low-density 
lipoprotein receptor-related protein (LRP) form a complex that sequesters GSK3β and Axin from 
the destruction complex which permits newly synthesized cytosolic β-catenin stabilization and 
accumulation triggering its translocation to the nucleus. [4] [5] Once there, β-catenin binds to T 
cell factor/lymphoid enhancer family (TCF/LEF) and converts it to an activated form for many 
growth genes, notably the oncogene c-Myc, cell cycle regulator cyclin D, the stem cell marker and 
agonist of the Wnt pathway LGR5, as well as Axin2 which is a global Wnt transcriptional target. 
[6] [4] [7] The movement of β-catenin from the cytoplasmic to nuclear emplacement has yet to 
be completely understood. A comprehensive schematic of Wnt signaling is presented in Figure 
1.3 below. 
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Figure 1.3. Wnt on and off signaling modified from [5] When Wnt signaling is off, APC 
destruction complex targets β-catenin for destruction and downstream target genes are not 
transcribed. When Wnt signaling in on, the APC complex is sequestered, synthesized β-catenin is 
stabilized and can translocate to the nucleus and upregulate downstream target genes and 
induce a Wnt phenotype. 
 
The small intestine epithelium is a classic model in mammalian Wnt signaling. The villi extend 
into the intestinal lumen and are the most rapidly renewed tissue in adult mammals with an 
entire turnover rate of 4-5 days. [4]  Each crypt is located at the base of these villi and extends 
into the submucosal membrane as a droplet-like invagination of cooperating cells. At the base of 
the crypts are differentiated Paneth cells and the intestinal Wnt-responsive intestinal stem cells, 
also known as LGR5 crypt base columnar (CBC) cells. Each crypt contains approximately 15 LGR5 
CBCs. [8] Local signaling by Paneth cells, which are strategically interspersed with CBCs in the 
crypt base, of both Wnt ligands and Rspondin ligands (whose receptor target is LGR5) act on ISCs 
to drive Wnt signaling [9].  Transit amplifying cells – progenitor cells that move upward and begin 
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to differentiate into the various specialized cells of the intestine - populate the villi of secretory 
(goblet, enteroendocrine, tuft and previously mentioned Paneth cells) or absorptive 
(enterocytes) cells. Paneth cells are the exception to this lineage differentiation model and do 
not migrate out of the crypt but rather migrate back down to the crypt base. [10] As an influx of 
new cells move up the villi, cells at the tip encounter an apoptotic fate and are steadily removed. 
Wnt signaling prevents the differentiation of ISCs in the stem cell niche, and the 
constitutive activation of the Wnt pathway causes cells that move up the epithelium to maintain 
ISC-like phenotypes including LGR5 expression and mitotic growth. [11] This is believed to be an 
important initial contributing factor to the development of CRC.  
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1.4 Circadian Rhythms 
 
A circadian rhythm is a 24-hr periodicity of behavioural and physiological processes that 
occur in organisms based on the Earth’s 24-hour rotation. Half of the Earth’s surface is exposed 
to the Sun’s light, creating day and night which has influenced daily activity and evolution as we 
know it. An organism’s ability to adapt its metabolism and activities based on the day-night cycle 
is thought to increase its fitness over time [12] [13] [14].  The temporal regulation of the 24-hour 
cycle, for example eating during the daytime and fasting at night, has influenced evolution on the 
cellular level. These day-night directives have contributed to cell specific circadian oscillators in 
a wide range of lifeforms. [15]  A circadian rhythm occurs in virtually all cells of the body in a cell-
autonomous, gene-driven, fashion orchestrated by the expression of genes, termed circadian 
clock genes [16].   
The circadian clock is organized hierarchically in mammals. The central circadian 
orchestration is directed by the suprachiasmatic nucleus (SCN) located deep in the central region 
of the hypothalamus where it receives light cues via the optic nerve. The SCN is very sensitive to 
light impulses. Phase shifts in rhythmicity can occur accordingly [17] and this information is sent 
to peripheral clocks of the body, synchronizing them.  Therefore, light cues incorporated into the 
body from the environment via this central clock entrain the system as a whole via neuronal and 
hormonal messages that travel systemically to induce circadian rhythms in peripheral tissues [17]  
This permits systemic rhythmicity and adaptability to new or changing environments imparting 
fitness of the system as a whole. Peripheral clocks of the body are composed of cell-autonomous 
oscillators that employ the same genetic clock machinery, but the output differs according to the 
organ system in question.   
  10 
1.5 Circadian Clock 
 
In the mammalian transcriptional-translational feedback loop (TTFL), there is a core 
transcription factor termed the Brain And Muscle ARNT-Like 1 (BMAL1). This is a basic helix-loop-
helix protein which dimerizes with the transactivator CLOCK to bind to the E-Box promoter site 
for the transcription of clock genes PERIOD and CRYPTOCHROME generating their proteins, PER1, 
PER2, PER3, and CRY1 and CRY2, respectively.  These proteins form a negative feedback repressor 
complex [17] that accumulates in the cytoplasm to then translocate back to the nucleus where it 
turns off its own gene transcription. In addition, there is a second feedback loop where 
BMAL1/CLOCK dimer regulates the transcription ofNr1d1/Nr1d2 nuclear receptors REVERB and 
REVERBβ respectively which will impart a repression of BMAL1 gene transcription. Overall these 
two systems of feedback, result in the oscillatory expression of core circadian genes, creating 
rhythmic transcription cycles.  
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Figure 1.4 Schematic of the circadian clock network. The core circadian clock mechanism is a cell-
autonomous transcriptional translational feedback loop linking CLOCK and BMAL1 and their target genes 
Per1,2 and Cry1,2, whose translated proteins form a repressor complex that creates a feedback loop. 
Additionally, there are other feedback loops driven by the core clock gene dimers CLOCK:BMAL1. A first 
such loop comprises REVERBs and RORs that are antiphasic to BMAL1 gene expression and that repress 
BMAL1 transcription. CLOCK:BMAL1 also govern downstream target gene expression termed clock-
controlled genes (CCG) which cause rhythmic biological processes in various tissue. Post translational 
modification and phosphorylation of Cry and Per target them for ubiquitination, allowing CLOCK:BMAL1 
to once again bind to E-boxes and begin again the cycle. Image modified from [15] 
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1.6 The clock and cancer/CRC 
 
There is an increased incidence of cancer in people exposed to chronic disrupted circadian 
rhythms, such as shift workers. In recent years, epidemiological studies have revealed a slight to 
moderate increase in risk for breast, colon, endometrial epithelial malignancies as well as non-
Hodgkin’s lymphoma in longtime night workers and shift workers. [18] [19]  It is unclear if this 
greater incidence is causal or incidental. The molecular links between the circadian clock and 
cancer remain unclear. Some studies have shown that loss of circadian function increased 
tumorigenesis while other conflicting research has shown that disrupting core clock components 
can decrease tumour growth and so this remains a contested area of study. 
A disrupted circadian organization has been linked to some of the hallmarks of cancer. 
[20] There is evidence that Per1 connects the circadian system and cell death, its overexpression 
sensitizes cancer cells to DNA damage-induced apoptosis while, inversely, its silencing conveys a 
blunted apoptotic progression. [21]  Upregulation/deregulation of the proto-oncogene cMyc is 
often associated with human cancers – where it plays a key role in cell growth. cMyc is a 
transcription factor whose structure is very similar to both the structures of CLOCK and BMAL1 
transcription factors. All are basic Helix-loop-Helix (bHLH) transcription factors that compete for 
binding to E-boxes in the promoter of many target genes, with 574 overlapping gene binding 
sites. [22] [23] Myc and its dimer partner MAX are functionally dominant over CLOCK/BMAL1 for 
E-box binding [22].  Elevated Myc expression is associated with the poorest clinical outcome in 
neuroblastoma patients as is elevated REVERBa. [23] Myc abnormal expression, as occurs in 
cancerous cells, results in an increase of target genes involved in metabolic processes such as 
glycolysis, oxidative metabolism, as well as mitochondrial and ribosomal biogenesis and cell cycle 
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regulation [24] As mentioned previously, genomic instability fuels cancer progression and can 
cause or be the consequence of transformation. Genomic instability has also been linked to Per1. 
[25] [21] One study investigated whether Per1 could influence the DNA damage response by 
modulating the ATM pathway and its downstream effector CHK2, a key cell cycle checkpoint 
protein. It was concluded that Per1 was necessary for effective activation of CHK2 when DNA was 
damaged through double strand breaks. [21]  Yet another lab looked at the impact of Per1 and 
Per2 on tumour growth and circadian organization and found that that tumour growth is 
coordinated by the circadian clock in vivo, and that depletion of these 2 genes enhanced tumour 
growth rate at certain times of the day. [20] Important to this thesis, the APCmin/+  mouse model, 
has also been used to investigate circadian rhythms’ disruption and its impact on colorectal 
cancer progression.  One lab demonstrated that a Per2 mutation accelerated APCmin  
tumorigenesis, increasing b-catenin levels and its target protein cyclin D. [26] Another found loss 
of Per2 showed a neoplastic growth phenotype [27]. Finally, there is some evidence that the 3rd 
homolog to the human Period protein, PER3, is downregulated in chronic myeloid leukemia, a 
variant PER3 genotype was associated with increased breast cancer risk, and its altered gene 
expression was identified in 203 Colorectal cancer patient samples. [28] [29] [30] Similarly, a 
recent study showed transplanted B16 cell tumours had suppressed clock genes but triggering 
circadian clock in these cells function inhibits tumorigenesis, slowing down tumour growth [31] 
However, since there are three homologs of the PER gene and these studies did not manipulate 
all Per genes simultaneously, the circadian clock is completely functional in the animals used in 
these studies suggesting it is not clock function that impacts cancer, but rather a non-clock 
function for the Per genes.    
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As mentioned above, research has unveiled conflicting views on the circadian rhythms’ 
impact on tumorigenesis. One such study found that suppressing the clock gene BMAL1 
promotes differentiation of Leukemia Stem Cells in acute myeloid leukemia (AML) and decreases 
the proportion of actively dividing cells, thereby reducing tumour progression [32]. This suggests 
that loss of clock gene activity decreases cancer rather than increases cancer. Another study 
found that overexpression of Per1 was shown to induce increased expression of cMyc in  HCT116 
cancer cell lines with a Per1 expression vector (HCT/PER1). [21] Most importantly, recent studies 
found that when p53 is mutated, as it is in more than 50% of cancers, in CRY1/2-/- mice enhances 
intrinsic (mitochondrial) and extrinsic (cytokines) apoptosis. These p53; CRY1/2 triple mutants, 
when treated with UV-mimetic agents (such as the chemotherapeutic oxaliplatin), actually have 
increased survival probabilities likely due to p53-independent intrinsic apoptosis. [33] Indeed, in 
a heroic effort to validate the previous research on Per genes mentioned above, a study tested 
both normal and irradiated Per1-/- and Per2 -/- mice only to find that these clock mutations alone 
do not make mice more tumour-prone. [34] These studies made careful tests of Per function by 
backcrossing mice on the same genetic background, a major source of error in the previous 
studies examining clock function. This body of differing data offers confounding information.  
Therefore the role of the circadian clock in cancer disease progression is an open 
question.  
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1.7 Hypothesis and Specific Aims 
 
The major objectives of this study were to investigate how tumours behave in comparison to 
normal intestinal tissue as well as to investigate tumorigenesis in a clock-dead CRC mouse model. 
I first hypothesized that transformed cells would have disrupted expression of circadian clock 
gene transcription. I furthermore hypothesized that tumorigenesis would increase under clock 
disruption in the APCmin/+ mouse cancer model. To test these hypotheses, the following aims were 
pursued: 
1. Investigate, using RT-qPCR, whether there are time-dependent differences in Wnt 
pathway targets, such as cMYC, AXIN2, and LGR5 as well as cell cycle promoter CyclinD, 
and whether there are differences in circadian clock components PER2, BMAL1, and REV-
ERB  within tumorous cells and the surrounding normal tissue in littermate APCmin/+ 
animals (addressed in Chapter 2). 
2. Investigate, through visual investigation and H&E staining, the impact of a disrupted 
circadian rhythm on tumorigenesis using the APCmin/+  mouse model system. Circadian 
rhythm disruption was carried out genetically, and tumours throughout the intestine 
were counted and measured (addressed in Chapter 3). 
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1.8 Materials and Methods 
 
Chapter 2  
 
Animals and Housing: 
Mice from the Jackson Laboratory (BL/6J-ApcMin/J Catalog Number. /ID: 002020) were bred 
to obtain APCmin/+ genetic makeup. They were bred and maintained with wild type littermates 
until 3 months. All samples were obtained at 3 months of age. Conditions in the animal quarters 
were maintained with a constant 12-hour light and 12-hour dark photoperiod. All Animal Care 
Committee (ACC) guidelines and University of Windsor Research Ethics Board for Animal 
Protocols were strictly respected. Water was sterile, and feeding was ad libitum.  
 
Tissue Collection: 
Animals were sacrificed at 4-hour intervals on the 24-hour cycle. Sample size was 5 
APCmin/+  and 3 APC +/+ per timepoint.  A total of 6 tumours and 6 adjacent tissue samples were 
taken per APCmin/+ animal (3 from the proximal intestine and 3 from the distal intestine) as well 
as 1 sample of tissue consisting of 1 blend of proximal and distal intestine from the negative 
control APC +/+. Following CCAC protocol, CO2 was administered followed by isolation of intestine. 
Whole intestine segments were stored in 8mL of RNAlater (Qiagen Cat No./ID: 74106) solution 
for 24 hours at 4°C followed by long-term storage at -80°C.  Intestine samples were collected at 
7 am, 11 am, 3 pm, 7 pm, 11 pm, and finally 3 am, or ZT0, ZT4, ZT8, ZT12, ZT16, and ZT20 
respectively. See figure below for visual representation of steps described above. 
  17 
 
Figure 1.5 Dissection of animals in preparation for RNA analysis. 6 timepoints, each with 
5 animals were analyzed. In each animal, 6 adenomatous overgrowths as well as 6 adjacent 
normal-looking epithelial tissue samples were extracted.  360 Tumour and Tissue samples total 
were analyzed as well as 18 APC+/+ negative controls.  
 
 
RNA extraction 
RNA extraction was accomplished by placing intestine sections on a Sylgard Plate (Dow 
Corning) along with some RNA later to maintain tissue integrity. Using a Zeiss Semi 2000 
sterioscope and its magnitude of 2.5x, tumours no greater than 27mm3 were sampled and placed 
in bullet blender tubes (Next Advance) containing 0.9 - 2.0 mm stainless steel beads (SS14B-RNA) 
in 30 µl of RNA later and kept on ice.  As described above, 3 tumours from proximal and from 
distal regions were excised along with a tissue sample from the adjacent intestinal epithelium 
without tumour formation. Total samples therefore per animal was 12 (n = 6 tumours and n = 6 
tissue). All samples were collected using sterile technique with a thorough cleaning using 70% 
In	RNAlater
for	analysis
Flushed	with	PBS
n	=		5	animals	at	4	hour	intervals	(6	
timepoints)
6	tumours	and	adjacent	tissues	/	animal	
(3	from	proximal	3	from	distal	regions	of	
intestine)
Total:	360	samples	tested	
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ethanol on instruments between samples in an RNase-free space ensured by wiping all 
equipment and work surfaces with RNAzap (Qiagen Cat No./ID: 74106). RNAeasy RNA extraction 
kit was used and hence forth all RNA extraction refers to Qiagen Cat No./ID: 74106.  Once all 
samples were collected, RNAlater was removed from bullet blender tubes, careful not to disturb 
the sample, and 600µl β-Mercaptoethanol (Aldrich, Cat No./ID: M6250) and RLT buffer mix at a 
1µl:100µl ratio, respectively. RNA-free filter pipette tips were used throughout the entire RNA 
extraction process. In 600 µl β-Mercaptoethanol : RLT buffer mix, samples were homogenized in 
a bullet blender for 4 minutes at speed 8. After a minute pause, samples were again subjected to 
shredding at speed 10 for 2 minutes. Subsequently, they were spun at 14 800 RPM for 3 minutes 
at 4 oC. Supernatant was removed and equal parts (600 µl) of 70% ethanol in RNAse-free water 
was added making sure to mix well with the supernatant. Supernatant: 70 % ethanol mix was 
added in 2 batched of 600 µl to an RNAeasy mini spin column and spun at 11 000 RPM for 1 
minute at 22 oC, with discard of lysate flow-through.  
250 µl of RW1 Buffer was added, spun at 11 000 RPM for 1 minute followed DNAse 
treatment for 15 minutes at room temperature in a 10 µl: 70 µl RDD buffer (Qiagen  Catalog 
No./ID: 79254) ratio. After this incubation, 350 µl RLT butter was added and samples were spun 
at 11 000 RPM discarding the flow-through. This was followed by twice adding 500 µl RPE buffer, 
spinning at 11 000 RPM and discarding the flow-though. Prior to adding water for the final RNA 
extraction step, samples were dried by spinning at 11 000 RPM in a fresh elution tube for 1 
minute. Columns were placed in a new labeled 1.5 mL Eppendorf tube and 40 µl of RNAse-free 
water (Ambion, Cat No./ID: AM9930) was added and incubated for 1 minute at room 
temperature. Samples were spun at 11 000 RPM. This was repeated. Extracted RNA was collected 
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labeled Eppendorfs and immediately placed on ice. Employing a NanoDrop ND-1000 
Spectrophotometre (ThermoScientific), 1 µl of each sample was analyzed for its yield in RNA 
concentration in ng/µl. 
cDNA synthesis was performed using 0.5 µg of RNA in each 20µL sample of cDNA using 
IScript protocol.   Amplified genes in samples included gene expression of GAPDH (used as an 
expression control as well as a normalization reference for all gene expression levels), BMAL1, 
PER2, REV-ERBα, CycD, cMYC, AXIN2, and LGR5. A primer set (PrimerBank) for each gene of 
interest was amplified at >90% efficiency, previously determined in our lab. The following primers 
were used: 
Target Forward Primer Reverse Primer 
GAPDH AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
BMAL1 TGACCCTCATGGAAGGTTAGAA GGACATTGCATTGCATGTTGG 
PER2 GAAAGCTGTCACCACCATAGAA AACTCGCACTTCCTTTTCAGG 
Reverb-α TGAACGCAGGAGGTGTGATTG GAGGACTGGAAGCTATTCTCAGA 
CycD GCGTACCCTGACACCAATCTC CTCCTCTTCGCACTTCTGCTC 
cMYC ATGCCCCTCAACGTGAACTTC GTCGCAGATGAAATAGGGCTG 
AXIN2 TGACTCTCCTTCCAGATCCCA TGCCCACACTAGGCTGACA 
LGR5 CCTACTCGAAGACTTACCCAGT GCATTGGGGTGAATGATAGCA 
Table 1.1 Primer details used in qPCR. 
RT-qPCR was done using a 384 well plate with 10 µl in each well. Each well consisted of 5 
µl of 2X QuantiIect SYBR Green (Qiagen Catalog No./ID: 204141), 3.2 µl RNAse-free water and 0.4 
µl each or forward and reverse primers at a 10pmol/µl concentration. To this, 1 µl of the cDNA 
  20 
sample was added. To ensure accuracy, wells were plated in duplicates, and data was used when 
duplicate critical threshold was <0.5 cycle standard deviation. Quantification was done using 
Viia7 Real-Time PCR system (Thermo Fisher Scientific). Critical threshold of >30 cycles (very low 
product abundance) were not used in the quantifications presented. 
Chapter 3 
 
Animal Housing:  
Mice from the Jackson Laboratory (C57BL/6J-ApcMin/J Catalog Number/ID: 002020) were 
bred to obtain the APCmin/+ genetic makeup.  Male APCmin/+ mice, wild type for the BMAL1 gene, 
were crossed with a second strain of BMAL1+/-  female mice (Jackson Laboratory B6.129Arntl tm1 
Bra/J Catalog Number/ID 009100), wild type for the APC gene. These two genetic backgrounds 
were crossed for > 4 generations of backcrosses until  they yielded male offspring of APCmin/+; 
BMAL1+/-  genotype as well as females of APC+/+ ; BMAL1+/-  genotype. These littermates were 
then backcrossed to obtain multiple generations of offspring containing the 4 genetic profiles for 
this project: APCmin/+ ; BMAL1-/- (n=12), APC+/+ ; BMAL1+/+  (n=12), APC+/+ ; BMAL1-/- (n=15), and 
APCmin/+; BMAL1+/+ (n=11).  All littermates were kept together until they reached maturation at 3 
months of age at which point samples were obtained at 2 timepoints in the 24-hour cycle – at 
ZT4 (morning) or ZT12 (evening). Conditions in the animal quarters were maintained with a 
constant 12-hour light and 12-hour dark photoperiod, all Animal Care Committee (ACC) 
guidelines and University of Windsor Research Ethics Board for Animal Protocols were strictly 
respected. Temperature and humidity were maintained at 22 ̊C and 55%, respectively and sterile 
water and feeding was ad libitum.  
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Tissue Acquisition: 
Animals were sacrificed by CO2 asphyxiation at 2 ml/min for 10 minutes followed by 
cervical dislocation. Body cavity was opened, and full intestine removed from start of duodenum 
to end of ileum.  Intestine was cut into 3 approximately even segments. A blunted 25g needle 
was inserted into the distal regions of each segment intestinal lumen was flushed using cold 1x 
Gibco Phosphate-buffered saline (PBS) then fixed for 2 hours in 4% paraformaldehyde at room 
temperature. Intestines were then rinsed 3X in PBS then allowed to dehydrate in 30% sucrose 
overnight or longer.   
 
 
Figure 1.6  Intestinal Tumour Count (A) Entire length of intestine was laid out and measured for 
partitioning into 4 equal segments. (B) Individual cut third segments were laid and tumour were 
counted in the measured quarter partitions. 
 
A
A 
B 
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Figure 1.7 Intestinal Tumours. Example of tumours greater than 1 mm are circled in red while 
less than 1mm in blue. A glass rod yardstick of 1mm in diameter was used to decipher size, if 
questionable. 
 
Quantification: 
Placing intestine sections on a Sylgard Plate (Dow Corning), the entire length of intestine 
was measured (Figure 1.6 A) to determine the total length. Adenomas/tumours were counted 
(Figure 1.6 B) in each quarter of this length using a Zeiss 2000 stereoscope. Tumours were 
qualified as being either greater than 1mm or less than 1mm in diameter (Figure 1.7) Intestinal 
samples were then Swiss-rolled and imbedded in optimal cutting temperature compound (OCT, 
Tissue-Tek, Sakura) and sectioned at 10µm and allowed 1 hour to dry before being stored at -20 
oC. Slides were removed from the 20 oC freezer and allowed 30 minutes to thaw. Slides were then 
stained for Hematoxylin and Eosin. First, slides were immersed in Ehrlich’s Hematoxylin Solution 
(26040-05, EMS) for 5 minutes, removed and incubated in acid alcohol (700mL 100% ethanol, 
390mL distilled H2O, 10mL HCl) for 30 seconds then moved to a wash of 0.1% Sodium Bicarbonate 
for one minute. Following the bicarb wash, slides were washed for 5 minutes in running tap 
water. Slides were then quickly washed in distilled water for 30 seconds. Second incubation in 
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Aqueous Eosin Y (1%, 26051-10, EMS) was for 5 minutes. Again, slides were washed in running 
tap water for 5 minutes then quickly washed in distilled water for 30 seconds. Slides were then 
dehydrated in a 2-step 95% ethanol each for 2 minutes and subsequently dehydrated more in a 
2-step 100% ethanol bath for 2 minutes each. They were then cleared twice for 15 minutes in 
Histoclear (64110-01, EMS) and mounted in Clearium, (13520-11, EMS) mounting media. Slides 
were scanned using AXIOscan.  
H&E slides were scanned using Axio Scan.Z1 to locate all tumours on a slide from APCmin/+ 
; BMAL1-/- (n=12) and APCmin/+ ; BMAL1+/+ (n=11). The genotypes APC+/+ ; BMAL1+/+  (n=12) and  
APC+/+ ; BMAL1-/- (n=15) did not have any significant tumours to justify staining and scanning of 
these samples.   
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Chapter 2 
 
 
RNA analysis investigating time-dependent differences in Wnt 
pathway and circadian clock targets in colorectal adenomas and 
adjacent healthy tissue 
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Results 
 
To assess expression levels of target genes in APCmin/+ induced tumours, we collected 
tumour and tissue samples (n=30 animals), extracted RNA, made cDNA and ran RT-qPCR analysis 
with GAPDH as a normalization control. Tissues were used as negative controls in APCmin/+  
animals.  However, the tissue samples were still from the tumour-prone mice. Therefore, APC+/+ 
littermates (n=18) were also sacrificed and expression of BMAL1, PER2, REVERB, CyclinD, cMyc, 
and AXIN2  were analyzed relative to GAPDH normalization control.   Results or RT-qPCR showed 
that tumours, except for a few outliers, showed lower expression of BMAL1 and PER2 clock 
genes, and to a lesser degree REVERB compared to the tissue adjacent to the tumour. We also 
saw an increased expression of Wnt, cell cycle progression, and stem cell marker genes. Tumours 
exhibited circadian rhythms like tissue and Wt, but these rhythms were dampened.  Results are 
summarized in Tables 2.1 and 2.2 following the figures below. 
The proximal and distal regions of the intestine were analyzed separately because these 
are functionally and morphologically distinct tissue regions. Expression of BMAL1 was less in 70 
% of proximal tumours (fig 2.1) and 90% in distal tumours (fig 2.2), and was at its highest 
between  ZT20 and ZT0 and its lowest between ZT8 and ZT12, in all samples. This mostly 
corresponds  to BMAL1 expression in our negative control (figs 2.2), with a slightly later peak 
expression in the Wt. Expression of Per2 was less in nearly 86% of proximal tumours (fig 2.3) 
and 90% in distal tumours (fig 2.4). Inversely to BMAL1, peak expression of Per2 in APCmin/+   
animals was at ZT12 and trough between ZT0-4. Our negative control had peak expression at 
ZT16 (figs 2.4) This constitutes a slight phase shift, meaning  peak expression has advanced 
slightly to earlier in the cycle in the APCmin/+ . Results for REVERB expression levels between 
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tumours and tissue were more mixed. Tumours in the proximal intestine expressed this gene 
less in only 63% of samples (fig 2.5). In the distal intestine, 71% of tumours expressed less 
REVERB than the tissue samples (fig 2.6). REVERB has an expression peak at ZT8 and a trough 
between ZT0, which compares to APCmin/+  expression. CyclinD expression was greater in 96% of 
tumours in the proximal intestine (fig 2.7) and in 81% of distal tumours (fig 2.8). The APCmin/+   
and Wt expression of cyclinD did not have significant expression rhythmicity.   Axin2 expression 
was more greatly expressed in 88% of proximal tumours (fig 2.9) and 82% of distal tumours 
(2.10). APCmin/+   and Wt animals had significant variations in expression levels between 
timepoints, but not in a 24-hour period circadian manor. This gene’s expression could be 
ultradian in nature, meaning shorter <24h repeated cycles within a day. cMyc expression had 
the most pronounced expression findings. cMyc was not rhythmic in APCmin/+  samples, but there 
was significant variation between the timepoints in the Wt tissue. 98% of tumours more greatly 
expressed cMyc in the proximal intestine (fig 2.11) and 96% did so in the distal region (fig 2.12).  
Lastly, 91% of tumours more greatly express the stem cell marker LGR5 in proximal tumours (fig 
2.13) as does 89% of distal tumours (fig 2.14). Overall these results showed that clock gene 
function is lower in tumour than in surrounding wildtype tissue, and that Wnt pathway 
dysfunction is higher in tumours than in surrounding tissue. 
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BMAL1 expression is less in 90% of Distal Tumours
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BMAL1 expression in APC+/+  negative 
control. Graph shows n=18 tissue 
samples. Quantification of BMAL1 
expression relative to GAPDH by qPCR 
in samples. 
 
ZT0 ZT4 ZT8 ZT12 ZT16 ZT20
0.00
0.01
0.02
0.03
E
x
p
re
s
s
io
n
 
(R
e
la
ti
v
e
 t
o
 G
A
P
D
H
)
Wt BMAL1
Figure 2.2 BMAL1 expression is reduced in 90% of distal tumours. Graph 
shows n=90 tumours and n=90 tissue in APC min/+ mice. Quantification of 
BMAL1 expression relative to GAPDH by qPCR in distal tumours (grey) and 
tissues (black). BMAL1 is a circadian clock gene and its diurnal rhythm in 
these samples shows a peak at ZT20 and a trough at ZT8. The diurnal 
changes in BMAL1 in tissue is significant (ANOVA, F (5, 84) = 29.07, 
P<0.0001) and the diurnal change in BMAL1 in tumour is also significant 
(ANOVA, F (5, 84) = 16.32, P<0.0001). Paired T-test indicates that 90% of 
samples measured have significantly lower expression of BMAL1 in tumours 
(p<0.0001).  There is a high variability in tumours and tissue. 
 
Figure 2.1 BMAL1 expression is reduced in 70% of proximal tumours. 
Graph shows n=90 tumours and n=90 tissue in APC min/+ mice. 
Quantification of BMAL1 expression relative to GAPDH by qPCR in proximal 
tumours (grey) and tissues (black). BMAL1 is a circadian clock gene and its 
diurnal rhythm in these samples shows a peak at ZT20 and a trough at ZT8. 
The diurnal changes in BMAL1 in tissue is significant (ANOVA, F (5, 84) = 
30.13 P<0.0001) and the diurnal change in BMAL1 in tumour is also 
significant (ANOVA, F (5, 84) = 16.75 P<0.0001) Paired T-test indicates that 
70% of samples measured have significantly lower expression of BMAL1 in 
tumours (p<0.0001). There is a high variability in tumours and tissue. 
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Per2 expression in APC+/+  negative 
control. Graph shows n=18 tissue 
samples. Quantification of Per2 
expression relative to GAPDH by qPCR 
in samples. 
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Figure 2.3 Per2 expression is reduced in 85.6% of proximal tumours. Graph 
shows n=90 tumours and n=90 tissue APC min/+ mice. Quantification of Per2 
expression relative to GAPDH by qPCR in proximal tumours (grey) and tissues 
(black). Per2 is a circadian clock gene and its diurnal rhythm in these samples 
shows a peak at. The diurnal changes in Per2 in tissue is significant (ANOVA, F 
(5, 84) = 21.57, P<0.0001) and the diurnal change in Per2 in tumour is also 
significant (ANOVA, F (5, 84) = 16.75, P<0.0001). Paired T-test indicates that 
85.6% of samples measured have significantly lower expression of Per2 in 
tumours (p<0.0001).  There is a high variability in tumours and tissue. 
 
Figure 2.4 Per2 expression is reduced in 90% of distal tumours. Graph shows 
n=90 tumours and n=90 tissue APC min/+ mice. Quantification of Per2 
expression relative to GAPDH by qPCR in distal tumours (grey) and tissues 
(black). Per2 is a circadian clock gene and its diurnal rhythm in these samples 
shows a peak at ZT12. The diurnal changes in Per2 in tissue is significant 
(ANOVA, F (5, 84) = 15.17, P<0.0001) and the diurnal change in Per2 in tumour 
is not significant (ANOVA, F (5, 84) = 2.106, P=0.726). Paired T-test indicates 
that 90% of samples measured have significantly lower expression of Per2 in 
tumours (p<0.0001). There is a high variability in tumours and tissue.    
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REVERBa expression is less in 71% of Distal Tumours
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REVERBa expression in APC+/+  
negative control. Graph shows n=18 
tissue samples. Quantification of 
REVERBa expression relative to 
GAPDH by qPCR in samples. 
 
Figure 2.6 REVERB expression is reduced in 71% of distal tumours. Graph 
shows n=90 tumours and n=90 tissue APC min/+ mice. Quantification of 
REVERB  expression relative to GAPDH by qPCR in distal tumours (grey) 
and tissues (black). REVERB  is a circadian clock gene and its diurnal 
rhythm in these samples shows a peak at ZT8. The diurnal changes in 
REVERB  in tissue is significant (ANOVA, F (5, 84) = 56.7, P<0.0001) and the 
diurnal change in REVERB  in tumour is also significant (ANOVA, F (5, 84) 
= 4.225, P=0.0018). Paired T-test indicates that 71% of samples measured 
have significantly lower expression of REVERB  in tumours (p<0.0001).  
There is a high variability in tumours and tissue. 
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Figure 2.5 REVERB expression is reduced in 63% of proximal tumours. 
Graph shows n=90 tumours and n=90 tissue APC min/+ mice. Quantification 
of REVERB  expression relative to GAPDH by qPCR in proximal tumours 
(grey) and tissues (black). REVERB  is a circadian clock gene and its diurnal 
rhythm in these samples shows a peak at ZT8. The diurnal changes in 
REVERB  in tissue is significant (ANOVA, F (5, 84) = 3.903, P=0.0031) and the 
diurnal change in REVERB  in tumour is also significant (ANOVA, F (5, 84) = 
26.8, P<0.0001). Paired T-test indicates that 63% of samples measured have 
significantly lower expression of REVERB  in tumours (p<0.0001).  There is 
a high variability in tumours and tissue. 
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cyclinD expression in APC+/+  negative 
control. Graph shows n=18 tissue 
samples. Quantification of cyclinD 
expression relative to GAPDH by qPCR 
in samples. 
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Figure 2.7 cyclinD expression is increas d in 96% of proximal tumours. 
Graph shows n=90 tumours and n=90 tissue APC min/+ mice. 
Quantification of cyclinD expression relative to GAPDH by qPCR in 
proximal tumours (grey) and tissues (black). Paired T-test indicates that 
96% of samples measured have significantly lower expression of cyclinD 
in tumours (p<0.0001).  There is a high variability in tumours and tissue. 
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Figure 2.8 cyclinD expression is increased in 81% of distal tumours. 
Graph shows n=90 tumours and n=90 tissue APC min/+ mice. 
Quantification of cyclinD expression relative to GAPDH by qPCR in distal 
tumours (grey) and tissues (black). Paired T-test indicates that 81% of 
samples measured have significantly lower expression of cyclinD in 
tumours (p<0.0001).  There is a high variability in tumours and tissue. 
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AXIN2 expression in APC+/+  negative 
control. Graph shows n=18 tissue 
samples. Quantification of AXIN2 
expression relative to GAPDH by qPCR in 
samples. The changes in AXIN2 
expression over a 24-hour period is 
significant in the Wt (ANOVA, F (5, 12) = 
4.017, P<0.0225) 
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Figure 2.10 AXIN2 expression is increased in 82% of distal tumours. 
Graph shows n=90 tumours and n=90 tissue APC min/+ mice. 
Quantification of AXIN2 expression relative to GAPDH by qPCR in distal 
tumours (black) and tissues (grey). Paired T-test indicates that 82% of 
samples measured have significantly lower expression of AXIN2 in 
tumours (p<0.0001).  There is a high variability in tumours and tissue. 
 
Figure 2.9 AXIN2 expression is increased in 88% of proximal tumours. 
Graph shows n=90 tumours and n=90 tissue APC min/+ mice. 
Quantification of AXIN2 expression relative to GAPDH by qPCR in 
proximal tumours (grey) and tissues (black). Paired T-test indicates that 
88% of samples measured have significantly lower expression of AXIN2 
in tumours (p<0.0001).  There is a high variability in tumours and tissue. 
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cMyc expression in APC+/+  negative 
control. Graph shows n=18 tissue 
samples. Quantification of cMyc 
expression relative to GAPDH by qPCR in 
samples. The changes in cMyc 
expression over a 24-hour period is 
significant in the Wt (ANOVA, F (5, 12) = 
5.959, p = 0.0054).  
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Figure 2.11 cMyc expression is increas d in 98% of proximal tumours. 
Graph shows n=90 tumours and n=90 tissue APC min/+ mice. 
Quantification of cMyc expression relative to GAPDH by qPCR in 
proximal tumours (grey) and tissues (black). Paired T-test indicates that 
98% of samples measured have significantly lower expression of cMyc 
in tumours (p<0.0001).  There is a high variability in tumours and tissue. 
 
Figure 2.12 cMyc expression is increased in 96% of distal tumours. 
Graph shows n=90 tumours and n=90 tissue APC min/+ mice. 
Quantification of cMyc expression relative to GAPDH by qPCR in distal 
tumours (grey) and tissues (black). Paired T-test indicates that 96% of 
samples measured have significantly lower expression of cMyc in 
tumours (p<0.0001).  There is a high variability in tumours and tissue. 
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Figure 2.13 LGR5 expression is increased in 91% of proximal tumours. Graph shows 
n=90 tumours and n=90 tissue APC min/+ mice. Quantification of LGR5 expression 
relative to GAPDH by qPCR in proximal tumours (grey) and tissues (black). Paired T-
test indicates that 91% of samples measured have significantly lower expression of 
LGR5 in tumours (p<0.0001).  There is a high variability in tumours and tissue.  
Figure 2.14 LGR5 expression is increased in 89% of distal tumours. Graph shows n=90 
tumours and n=90 tissue APC min/+ mice. Quantification of LGR5 expression relative to 
GAPDH by qPCR in distal tumours (grey) and tissues (black). Paired T-test indicates that 
89% of samples measured have significantly lower expression of LGR5 in tumours 
(p<0.0001). There is a high variability in tumours and tissue. 
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Wild-Type 
Gene 
(Clock gene) 
 
Correlates with 
APC min/+ 
Expression 
rhythms? 
 
 
Peak 
expression 
 
 
Trough 
expression 
 
Time-of-day difference in 
expression 
Anova value 
BMAL1 Slight phase shift ZT4 ZT12 Yes p<0.0001 
Per2 Yes ZT16 ZT4 Yes p<0.0001 
REVERB Yes ZT8 ZT0 Yes p<0.0001 
cyclinD Yes N/A N/A No p>0.05 
AXIN2 Yes ZT0,8,16 ZT4,12,20 Yes p = 0.0225 (3 peaks/24-hr) 
cMyc No ZT20 Zt0,16 Yes p = 0.0054 
 
APC min/+ 
Gene 
 (Clock gene) 
 
 
 
Higher/ Lower 
than Tissue 
Proximal - Distal 
 
 
Peak 
expression 
 
 
Trough 
expression 
 
Tumour vs Tissue 
T test value 
 
Time-of-day difference 
in expression 
Anova value 
BMAL1 Lower 
70% - 90% 
ZT20-ZT0 ZT8-ZT12 Lower p<0.0001 Yes p<0.0001 
Per2 Lower 
86%-90% 
ZT12 ZT0-ZT4 Lower p<0.0001 Yes p<0.0001 
(not in distal tumours  
p = 0.726) 
REVERB Lower 
63%-71% 
ZT8 ZT0 Lower p<0.0001 
p=0.0031 tumours 
Yes p0.0031 
 
cyclinD Higher 
97%-80% 
N/A N/A Higher p<0.0001 No p>0.05 
AXIN2 Higher 
85%-82% 
Not defined Not defined Higher p<0.0001 
 
Yes p0.0092  
cMyc Higher 
98%-96% 
Not defined Not defined Higher p<0.0001 No p>0.05 
LGR5 Higher 
91%-89% 
N/A N/A Higher p<0.0001 No p>0.05 
Table 2.1 Summary of results APC+/+ 
 
Table 2.2 Summary of results APCmin/+ 
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2.15 Expression of studied genes at all timepoints. 30 paired tumour and tissue samples at each 
timepoint in APC min/+ mice. Graph shows a summary of tumours having less expression than 
adjacent tissue (grey) and tissues having more expression than tumours (blue). All expression 
levels were normalized to GAPDH. Tumours express less circadian genes than their tissue 
counterparts in the majority of samples at nearly all timepoints examined. In contrast, the Wnt 
pathway target genes: CyclinD, cMyc, AXIN2 and LGR5 are all more greatly expressed in tumours 
compared to their tissue counterparts. These results highlight the lowered circadian clock 
function, and heightened Wnt pathway function occurring in APCmin/+ adenomas. 
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Chapter 3: 
Tumour burden with BMAL1 mutation in the APCmin/+ background 
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Results 
 
To test the hypothesis that clock disruption increases tumorigenesis, the APCmin/+ and 
BMAL1+/- strains, that are both from the BL6 background, were crossed. Littermates of 4 different 
genotypes: APC+/+; BMAL1+/+ (n=12), APC+/+; BMAL1-/- (n=15), APCmin/+ ; BMAL1+/+ (n=11),  and 
APCmin/+ ; BMAL1-/- (n=12) were collected and examined at 3 months of age. These littermates 
were collected between 3-7 generations after the initial crosses in order to achieve offspring with 
fewer differences in genetic modifiers that would influence the phenotype. Half were sacrificed 
at ZT4 while the other half at ZT12 to test possible time-dependent changes using these samples 
at a later date. Intestines were collected as described in the methods for the analyses presented 
in this thesis, but blood and stool samples were also collected for future blood hormone and 
cytokine analysis and microbiome testing. There is no significant tumour formation in the wild-
type APC+/+; BMAL1+/+ as well as in the APC+/+; BMAL1-/- mutant. This indicates that BMAL1 
mutation alone does not induce intestinal tumours. In contrast, a 2-fold increase in >1mm size 
tumour counts was noted in the APCmin/+; BMAL1-/-  compared to their APCmin/+; BMAL1+/+ 
littermates, and an increase in <1mm size tumours numbers in was also noted in this strain in the 
proximal regions of the intestine. This raised the question of whether the loss of BMAL1 in the 
CRC background generally increased tumour proliferation. Analyses of tumour size revealed the 
size of tumours is greater in the proximal intestine of APCmin/+; BMAL1+/+ compared to APCmin/+; 
BMAL1-/-. These results show that BMAL1 loss induces more tumour formation, but does not 
impact size in any region of the intestine except the proximal region where tumour size is smaller, 
even though the tumours are much more abundant. An explanation for this result could be that 
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in the proximal intestine, when BMAL1 is lost, tumours are induces earlier and therefore are 
more abundant, but not yet any larger in size. 
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Figure 3.1 Total tumour counts in study.  Graph shows the number of tumours found in each 
individual intestine wholemount. No significant tumours were found in either APC+/+; 
BMAL1+/+and APC+/+; BMAL1-/- genotypes. There is a significant increase in the number of 
tumours found in APCmin/+; BMAL1-/- mutants compared to APCmin/+; BMAL1+/+ wildtypes (*ANOVA 
F (3, 47) = 174.9, p <0.0001).       
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Figure 3.2 Tumours counts > 1mm.  Graph shows the number of tumours found in each individual 
intestine wholemount. No significant tumours were found in either APC+/+; BMAL1+/+and APC+/+; BMAL1-
/- genotypes. There is a significant increase in the number of tumours found in APCmin/+; BMAL1-/- mutants 
compared to APCmin/+; BMAL1+/+ wildtypes (*ANOVA F (3, 46) = 80.63, p<0.0001).      
 
  
  
 
Figure 3.3 Tumours of  < 1mm. Graph shows the number of tumours found in each individual intestine 
wholemount. No significant tumours were found in either APC+/+; BMAL1+/+and APC+/+; BMAL1-/- 
genotypes. There is a significant increase in the number of tumours found in APCmin/+; BMAL1-/- mutants 
compared to APCmin/+; BMAL1+/+ wildtypes (*ANOVA F (3, 46) = 58.51, p<0.0001).    
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Figure 3.4 Tumours of > 1mm size in D regions of intestine are increased in the BMAL1 mutant. 
Graph show the number of tumours found in each individual intestine wholemount. There is a 
significant increase in size in the distal regions of the BMAL1 mutants (*ANOVA F (7, 84) = 11.09, 
p = 0.0013). 
 
 
Figure 3.5 Tumours of < 1mm size in P and M1 regions of intestine are increased in the BMAL1 
mutant. Graph show the number of tumours found in each individual intestine wholemount. 
There is a significant increase in the number of <1mm tumours in APCmin/+; BMAL1-/- mutants 
compared to APCmin/+; BMAL1+/+ wildtypes in proximal and medial1 sections (*ANOVA F (7, 84) = 
9.69, p = 0.0006 ; ** ANOVA F (7, 84) = 9.69, p = 0. 0337).       
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Figure 3.6 Swiss role of BMAL1 wt, APC-induced CRC intestine. Image shows H&E staining of 
the APCmin/+; BMAL1+/+ genotype imaged on a slide scanner. Tumours are pseudocoloured in 
red. Note tumour size is larger than BMAL1mutant shown in Fig 3.7 
 
 
 
 
Figure 3.7 Swiss role of BMAL1 mutant, APC-induced CRC intestine. Image shows H&E staining 
of the APCmin/+; BMAL1 -/- genotype imaged on a slide scanner. Tumours are pseudocoloured in 
red. Note tumour size is smaller than wildtype control shown in Fig 3.6 
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Figure 3.8 Averages of tumour sizes in µm2.  Average Proximal, Medial and Distal (P, M, D) sizes 
in both APCmin/+ ; BMAL1-/- and APCmin/+ ; BMAl1+/+. Significantly less tumours size in P region of 
APCmin/+ ; BMAL1-/-  mice * p = 0.0019  No significance was found in the M and D regions. 
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Chapter 4: 
Discussion and Future Directives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  45 
 
Discussion and Future Directives 
 
 
 Our Earth’s rotation creates 24-hour periodicity of day and night - a natural condition that 
has influenced all life forms. Organisms that have evolved the best adaptation, meaning they’ve 
been able to anticipate timing of their daily activity, have increased their fitness. [14] Efficient 
timing of circadian clocks throughout the body helps maintain health of the whole system. [35] 
The mouse model is an experimental system that has proven extremely valuable in its capacity 
to model human disease. This is largely due to the genetic and genomic similarities between both 
organisms. Disease-related genes, such as APCmin/+ causing the initial transformation to an  
adenoma, as well as mammalian circadian and Wnt genes are the same in both humans and mice. 
Additionally, although the diurnal activity of humans does not directly correspond to the 
nocturnal activity of mice, this study does offer insight into how tumours behave and the impact 
of the clock on CRC tumorigenesis.  This project sought to investigate a) the impact of CRC on 
intestinal clock expression and b) the impact on disrupting the clock on CRC progression.  
 
Dampened clock expression 
 To begin, I found that expression of clock genes BMAL1, Per2, and REVERBα is dampened 
in tumours even if they still maintain appropriate rhythmicity. These clock genes have 
consistently lower expression in more tumours in the proximal intestines compared to the distal 
intestine. The rhythmicity for BMAL1, Per2, and REVERBα are generally similar to the Wt 
expression rhythmicity. I can speculate as to the influences in these dampened circadian 
expression levels in tumours.  Based on research demonstrating that overexpression of cMyc 
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attenuates the circadian clock [22] and Myc opposes E-Box-driven expression of Per 1 [36], it is 
likely that cMyc is implicated. cMyc is more greatly expressed in tumours in nearly 100% of the 
samples. Circadian/metabolism connections have been extensively studied. In cancer, 
upregulating cellular signaling pathways involved in cell growth influence energy metabolism. [2]  
Could it be possible that the dampened circadian expression as well as the larger percentages of 
tumours with a decreased expression are due to different metabolic functions of the proximal 
region of the intestine?  
 
 Tumour growth and metabolic exploration 
Consistent with the findings of cMyc expression, cyclinD is more greatly expressed in a 
higher percentage of tumours of the proximal intestine – 97% of proximal tumours have a greater 
cyclinD expression compared to 80% in distal tumours.  I can speculate that because tumours are 
more proliferative (greater cyclinD), there is increased metabolic SIRT1 and clock 
downregulation. cMyc may be at a critical cross between metabolism, oncogenesis and a 
disrupted clock.  I remind the reader that overexpression experiments of cMyc have shown that 
Myc;Max are functionally dominant over CLOCK; BMAL1 binding to E-Boxes, which  upregulate 
repressors components of the clock’s feedback loop, specifically Per2, Cry1 and very importantly, 
REVERBα. [23] Per2, Cry1 and REVERB α in turn repress CLOCK and BMAL1 expression in the 
feedback loop. Upregulation of cMyc in tumours analyzed may be what is upregulating REVERB 
relative to Per2 and BMAL1.  Since highly expressed Myc correlates to dampened circadian 
expression, and inversely, low expression of Myc correlates to a more robust amplitude in 
circadian expression, as is seen in these data, it is possible that Myc greatly contributes to the 
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tumour cell’s inhibition of circadian gene expression. Myc is a well-known oncogene that drives 
cancer, and adenoma formation in APCmin/+ is blocked when co-deletion of cMyc occurs. [8] 
Another study surmised that Myc was a link between oncogenic transformation, metabolic and 
circadian dysrhythmia which is advantageous for cancer growth. [23] It would be advantageous 
in future to look at metabolomics focusing on glucose, lactate, glutamine or glutamate levels in 
tumour and tissue to investigate altered metabolism in correlation with cMyc and Circadian gene 
expression. We see in these results, also, that REVERB levels are dampened in tumours, but not 
as greatly as Per2 and BMAL1, possibly induced by cMyc as mentioned above. Poor 
neuroblastoma prognosis is associated with increased REVERB expression. In a very remarkable 
recent study, REVERB agonists were shown to selectively target slowly proliferating tumorigenic 
and premalignant cell populations, possibly by blocking metabolic activity in these cells.  [37] One 
important caveat regarding the interpretation of this study deals with the nature of RNA levels. 
Future studies should confirm the findings of this present study by investigation protein levels in 
tumours and tissue. There could there be differences in either RNA and the corresponding 
protein levels that are not communicated accurately in the investigation RNA levels alone and 
given that proteins are the functional components of genes upon their translation in the 
cytoplasm, this will be an important next step in the investigation. 
Metabolism itself has also been demonstrated to influence clock expression through 
SIRT1 via the activity of NAMPT.  It is suggested that SIRT is driven by CLOCK; BMAL1 binding to 
E-box promoter of NAMPT and a negative feedback loop where SIRT1 then translocated to the 
nucleus and blocks binding of CLOCK; BMAL1. [38] It may be that the nature of the proximal 
intestinal metabolic function is such that in tumours from this regions, there is a greater 
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downregulation of circadian expression. Induction of early-stage transformed cells may have an 
earlier onset in the proximal intestine. One observation I made during animal dissections was 
that there is a large increase in fat tissue found in both APC +/+ ; BMAL1 -/- and APC min/+ ; BMAL1 -
/- mice.  Moreover, being overweight or obese is linked with an increased risk of many types of 
cancer, including CRC. [39] These observations suggest BMAL1 loss drives obesity and could 
provide a basic insight into the metabolic dysrhythmia associated with cancer in the  predisposed 
CRC in the APC min/+ mouse without circadian machinery.   
  
Clock deregulation and tumorigenesis 
As mentioned in the introduction, earlier research had shown that Per1 gene was 
necessary for effective DNA damage repair and reduced growth in cancer cells [21], and another 
found increased Per2 prevented tumour growth. [20] Others found Per3 was downregulated in 
chronic myeloid leukemia [28] while another concluded that Per2 mutant mice had a neoplastic 
phenotype and were cancer prone. [27] These older studies have been more recently challenged 
in findings where the investigators found cell lines with mutations in the circadian machinery 
were indistinguishable from their wild-type counterparts when it came to DNA damage response 
[39] Also, other research revealed errors in the methodologies of the earlier Period investigations 
using careful backcrossing of mice carrying the Per mutations on the same genetic background. 
[33] [34] The overall implication of these failure to replicate studies, is that single Period gene 
mutations cannot drive cancer.  
There are additional reasons why the clock cannot be implicated in these early Period 
mutant studies. Period genes have 3 homologs in mammals. If one is missing, others will 
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compensate for their loss and rhythmicity will still occur. In other words, missing one of the 
Period genes does not constitute a clock-dead model (Period proteins also have non-clock 
functions). It thus seems likely that the tumorigenicity observed was a result of unknown 
oncogenic activation or tumour suppression inactivation in their genetic background. My findings 
support these newer reports. I found no increase in tumour formation in the BMAL1-/-mutant 
mice. However, this fails to address whether truly clock-dead mice would develop spontaneous 
carcinogenesis when aged.  Cry1-/- and Cry2-/- mice irradiated at 8 weeks were indistinguishable 
to Wild type mice as were Per1-/-  and Per2-/- mice in 2 separate and more recent studies. [33] 
Therefore, observing BMAL1-/-mice for 80-90 weeks would shed light on tumorigenesis in this 
population. Based on this study, it appears that another underlying genetic mutation 
predisposing an animal to cancer, such as loss of APCmin/+, is necessary for the circadian clock to 
promote tumour induction. Another important consideration for results from this study is that 
while reducing genetic variation between samples by backcrossing for 4-5 generations was 
important, this reduction was not enough to eliminate absolutely the possibility of having other 
genetic variability affecting our results. Many generations more of backcrossing would need to 
occur for the results to be completely eliminate phenotype modifiers. A next step in the 
investigation of clock genes and CRC would be to investigate clock gene expression in different 
known stages of tumours – possibly human samples – in order to better elucidate changes in 
clock gene expression in the adenoma-carcinoma progression. 
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 BMAL1  
Previous studies have manipulated the gene BMAL1 in the context of cancer. It was 
identified that AML cells needed increased BMAL1 expression in order to proliferate and its 
downregulation halted proliferation. [32] These were studies in cell culture contrastingly to this 
study, which is in vivo, whole animal.  Although not directly comparable due to the difference in 
nature of the two kinds of studies, it does offer a disagreement with the findings of my research. 
It could be that the AML findings were tissue or cell specific or that it was a result of the isolation 
of cells in vitro. Alternatively, in vivo systemic alteration in the clock implicating a myriad of 
interactions that occur in the whole organism could be at play for the increased induction of 
tumours that I have discovered. Of course, my results, which tested the whole mutant BMAL1 
animal, are also a source of error as these effects could be taking place anywhere in the body or 
during its development. Also and as mentioned previously, 3-7 generations of backcrossing was 
likely not sufficient to remove any modifiers in the genes that may influence phenotype. Early 
induction of tumour phenotype may be at work here. In order to accurately investigate the tissue-
specific impact of the clock and intestinal tumorigenesis, future studies will need to investigate 
BMAL1 floxed mice with conditional KO in intestinal epithelium only and also only after 
development.  Two strains of mice would need to be crossed: mice with cre recombinase driven 
by a Villin promotor and BMAL1 Fl/Fl. This would test BMAL1 loss in the intestinal epithelium only. 
If a Villin-CreERT2 strain was used, mice could be injected with tamoxifen during only adulthood 
to conditionally delete BMAL1 in the intestine and avoid developmental effects. In both of these 
conditional experiments, these mice would have intact SCNs and all other peripheral clocks, just 
not in the intestine. Finally,  another follow-up experiment that could also test a disrupted clock 
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and its impact on tumorigenesis would be to disrupt photoperiods in mice and/or restricted 
feeding in APCmin/+ mice without BMAL1 mutation. The results of these studies could be compared 
and informative to see if the effects I observed were due to clock function in non-intestinal 
tissues, or during development. 
It is possible the tumour increases I observe are due to non-autonomous effects, so 
experiments complementary to the conditional KO would be informative. Additional insight 
would be to analyze the microbiome in BMAL1 -/- comparatively to BMAL1+/+. It was collected in 
this project, but not yet analyzed. It will be an important addition since it may elucidate if the 
intestinal flora population in the intestine of clock-dead mice differs from the Wt counterpart 
and if this somehow correlates to tumorigenesis. I also collected blood for analysis of 
corticosteroids and serum to investigate systemic pro-inflammatory cytokines from each cohort 
in efforts to tease out stress responses and inflammatory responses in tumorigenesis in clock-
dead mice.   
 
Stem cell marker LGR5 
LGR5, the ISC marker, has also been explored in hopes to unveil if tumours are an 
undifferentiated cell population. The tumours express greater LGR5 compared to the adjacent 
tissue – 90% of tumours have greater LGR5 expression. Likely, the cells of these tumours are non-
differentiated, even if they have moved above the differentiation line at the top of the crypts. 
Could this be due to an “inverted” crypt formation up into the villi – due to a perceived continual 
Wnt signaling from the extracellular environment? The lack of cellular differentiation and 
subsequent proliferation sets up the stage for additional replication errors, deregulated 
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metabolism, deregulated apoptotic measures from the cell and transformation. Future 
investigation looking at Rspondin levels in the cell population of CRC adenomas could help with 
understanding if Paneth cells also populate the adenoma, sending these Wnt agonists for 
sustained growth.  
  
 Tumour numbers vs. size 
H&E staining allows us to scan and make precise measurements of the tumours’ areas (in 
µm2) from 10µm slide sections. In accordance with the increased tumour numbers between both 
groups that is observed, random sections on slides from APCmin/+ ; BMAL1+/+ samples have 23 and 
24 tumours located and measured in the proximal and medial intestines, respectively, while 
APCmin/+ ; BMAL1-/- have 59 measured distinct tumours in both respective regions – approximately 
2.5 times more tumours on these slides. In the distal regions of both cohorts, there is no 
significant difference in number of tumours found for measurement. This coincides with the 
increase in tumour numbers found during wholemount counting. However, although the 
proximal region for the BMAL1 mutants have more tumours, their sizes, in general, are 
significantly smaller. The increase in tumour numbers – especially in the proximal intestinal 
region – with a smaller average size was indeed a surprise finding. When whole mounting and 
counting the tumours in APCmin/+ ; BMAL1-/- , my recurrent general observation was that there 
were many more tumours, but there were often very small in size. Why could there be more , 
but those present smaller? If it were a growth inhibition, tumour numbers would be similar 
between BMAL1+/+ and BMAL1-/- , but the former has fewer tumours that are, on average,  
greater in size.  It is possible that a BMAL1-/- mutation induces earlier adenoma formation, 
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accounting for their increased numbers, but decreased size in general.  These results suggest that 
the loss of BMAL1 affects tumour induction, but not proliferation, generally, in advancing 
tumorigenesis. There are many mechanisms that would explain this including changes in the 
number of stem cells and/or Wnt signaling, and changes in DNA damage response – both 
possibilities are worth examining in future work. 
Conclusion  
 
I found that expression of clock genes BMAL1, Per2, and REVERBα is dampened in 
tumours even if they still maintain appropriate rhythmicity. Conversely, Wnt target genes AXIN2, 
cMyc and cyclinD all more greatly expressed in adenomas. The stem cell marker LGR5 is also more 
greatly expressed in adenomas, implying an inverse affiliation between the circadian clock and 
growth. There are more tumours in the APCmin/+  CRC model system when BMAL1 is lost, but these 
tumours are not greater in size, suggesting that tumours suppress the circadian clock and that its 
complete loss promotes tumour numbers.  
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